Close Menu

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week released data from an ongoing Phase II open-label extension study of its TTR-mediated amyloidosis therapy patisiran, which showed that the drug treatment was associated with a stabilization of neurological impairment progression in patients with a form of the disease called familial amyloidotic polyneuropathy (FAP) after six months.

Investors responded positively to the news, sending shares of Alnylam up more than 20 percent in mid-Monday trading on the Nasdaq to $89.07.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.

Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.

A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.

In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.